期刊文献+

多囊卵巢综合征应用二甲双胍和炔雌醇环丙孕酮片的临床效果及对相关激素分泌水平的影响评价 被引量:1

Clinical efficacy of metformin and ethinyl estradiol cyproterone tablets in patients with polycystic ovary syndrome and their effects on the secretion of related hormones
下载PDF
导出
摘要 目的研究并探讨应用二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床效果及对其激素分泌水平的影响。方法选择2015年5月~2017年5月期间共77例多囊卵巢综合征患者,在计算机中按照随机数字表法将患者分为两组,对照组(37例)给予炔雌醇环丙孕酮片,观察组(40例)给予炔雌醇环丙孕酮片+二甲双胍,比较两组临床疗效、激素水平、不良反应。结果观察组总有效率高于对照组(P<0.05);治疗后,观察组LH、FSH、E2等激素水平均高于对照组(P<0.05);组间不良反应发生率比较,差异无统计学意义。结论联用二甲双胍、炔雌醇环丙孕酮片可提高多囊卵巢综合征的临床疗效,促进其激素分泌,且用药安全性可靠。 Objective To study and explore the clinical effect of metformin combined with Ethinylestradiol and Cyproterone Acetate Tablets in the treatment of polycystic ovary syndrome(PCOS)and its effect on the level of hormone secretion.Methods 77 patients with polycystic ovary syndrome were selected during the period of May 2015-May 2017.The patients were divided into 2 groups according to the random digital table method.The control group(37 cases)was given Ethinylestradiol and Cyproterone Acetate Tablets,and the observation group(40 cases)was given Ethinylestradiol and Cyproterone Acetate Tablets+two metformin,the clinical efficacy,the hormone water and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).After the treatment,the levels of LH,FSH and E2 in the observation group were higher than those of the control group(P<0.05),and there was no significant difference in the incidence of adverse reactions between two groups.Conclusion Combined use of metformin and Ethinylestradiol and Cyproterone Acetate Tablets can improve the clinical efficacy of polycystic ovary syndrome and promote the secretion of hormone,and the safety of drug use is reliable.
作者 熊夏思 Xiong Xiasi(Department of Gynecology,Jiangxi Maternal and Child Health Hospital,Nanchang,Jiangxi,330006,China)
出处 《当代医学》 2018年第23期105-107,共3页 Contemporary Medicine
关键词 多囊卵巢综合征 炔雌醇环丙孕酮片 二甲双胍 Polycystic ovary syndrome Ethinylestradiol and Cyproterone Acetate Tablets Metformin
  • 相关文献

参考文献10

二级参考文献96

  • 1DIAZ M, CHACON M R, LOPEZ-BERMEJO A, et al. Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue[J]. J Clin Endocrinol Metab, 2012, 97(10): 3630-3638.
  • 2CINAR N, HARMANCI A, BAYRAKTAR M, et al. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome[J]. Clin Endocrinol, 2013, 78(3): 379-384.
  • 3CHRISTAKOU C, KOLLIAS A, PIPERI C, et al. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers[J]. Hormones, 2015, 13(4): 488-497.
  • 4GLINTBORG D, MUMM H, ALTINOK M L, et al. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome[J]. J Endocrinol Invest, 2014, 37(8): 757-764.
  • 5GANIE M A, KHURANA M L, NISAR S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study[J]. J Clin Endocrinol Metab, 2013, 98(9): 3599-3607.
  • 6KAYA M G, CALAPKORUR B, KARACA Z, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome[J]. Clin Endocrinol, 2012, 77(6): 885-892.
  • 7GODE F, KARAGOZ C, POSACI C, et al. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate[J]. Arch Gynecol Obstet, 2011, 284(4): 923-929.
  • 8WILLIAMS R M, ONG K K, DUNGER D B. Polycystic ovarian syndrome during puberty and adolescence[J]. Mol Cell Endocrinol, 2013, 373(1/2): 61-67.
  • 9Geisthovel F. A comment on the European Society of HumanReproduction and Embryology/American Society forReproductive Medicine consensus of the polycystic ovariansyndrome[J]. Reprod Biomed Online,2003,7(6):602.
  • 10Cagnaeci A,Paoletti AM,Renzi A. Glucose metabolismand insulin resistance in women with polycystic ovarysyndrome during therapy with oral contraceptives containingcyproterone acetate or desogestrel [J]. J Clin EndocfinolMetab,2003,88(8):3 621.

共引文献297

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部